Value and income investors typically seek out dividend stocks that are trading below their intrinsic values. There are many quality dividend stocks trading near their 52-week lows that are attractive, due to their low valuation multiples and high dividend yields.

However, dividend growth investors should not avoid quality dividend growth stocks just because their share prices have risen over the past year. Indeed, there is good reason for investors to let their blue-chip winners run.

These 3 blue chip stocks are trading within 10% of their 52-week high, but could still generate strong returns in the years ahead.

Stryker Corporation (SYK)

Stryker is a global leader in the medical device sector. The company’s product lines include surgical equipment, neurovascular products and orthopedic implants.

On December 10th, 2024, Stryker reported that it was raising its quarterly dividend 5% to $0.84 per share, extending the company’s dividend growth streak to 31 consecutive years.

On January 6th, 2025, Stryker announced that it had agreed to buy Inari Medical, Inc. (NARI), which manufacturers
neurovascular medical devices, for $4.9 billion in cash. The transaction is expected to close by the end of Q1 2025.

On May 1st, 2025, Stryker reported first quarter earnings results for the period ending March 31st, 2025. For the quarter, revenue grew 11.9% to $5.9 billion, which was $210 million better than expected. Adjusted earnings-per-share of $2.84 compared favorably to $2.50 in the prior year and was $0.11 above estimates.

Organic revenue was higher by 10.1% for the quarter. For the period, volume grew 9.4% and higher prices added 0.7% to results. MedSurg and Neurotechnology had sales of $3.5 billion, which represented 10.7% organic growth, while Orthopaedics and Spine was higher by 9.3% to $2.4 billion.

Stryker has grown earnings-per-share at a rate of 13.9% per year since 2015 and 12.4% over the last five years. We reaffirm our earnings growth rate of 12%.

As the leader in the medical device sector, Stryker’s products are in demand around the world. For example, the company continues to see growth in its Mako robot installations, as well as a higher number of procedures performed. These figures are likely to grow as more surgeons become comfortable with using a robot during surgery.

Corteva Inc. (CTVA)

Corteva is an agricultural specialty business that is based in Indiana. The company operates two major segments: Seed, and Crop Protection.

The Seed segment develops and supplies advanced germplasm and traits that help improve yields for farmers. The segment focuses on technologies that boost resistance to weather, disease, insects, and weeds.

The Crop Protection segment offers products that protect against weeds, insects and pests, diseases, etc.

Corteva posted fourth quarter and full-year earnings on February 6th, 2025, and results were somewhat weak. The company’s net loss improved to $41 million, an improvement from the $253 million loss in the year-ago period.

Adjusted earnings were 32 cents per share, a penny ahead of estimates at 31 cents.

Revenue was 7% higher from a year ago to $3.98 billion, but missed consensus by about $30 million. Sales volume increased 17% as Crop Protection saw a 16% gain.

This was mostly attributed to Latin America, while volume in the Seed segment soared 19% year-over-year because of Safrinha corn that was planted in Brazil.

Corteva has broad and deep scale in the agricultural industry, but there is little it can do about the inherent volatility in the industry. This year should be record earnings, and roughly double what was produced in 2024.

S&P Global (SPGI)

S&P Global is a worldwide provider of financial services and business information and revenue of over $13 billion.

Through its various segments, it provides credit ratings, benchmarks and indices, analytics, and other data to commodity market participants, capital markets, and automotive markets.

S&P Global has paid dividends continuously since 1937 and has increased its payout for 51 consecutive years.

S&P posted fourth quarter and full-year earnings on February 11th, 2025, and results were much better than expected on both the top and bottom lines.

Adjusted earnings-per-share came to $3.77, which was a staggering 30 cents ahead of estimates. Earnings rose from $3.13 a year ago.

Revenue was up 14% year-over-year to $3.59 billion, beating estimates by $90 million. The company posted revenue growth in all of its operating segments, in addition to strong operating margin expansion.

Operating expenses rose slightly from $2.26 billion to $2.33 billion year-over-year. That led to operating profit of $1.68 billion, sharply higher from $1.39 billion a year ago.

With dividend growth above 10%, SPGI is one of the rock solid dividend stocks.